NCT00489372View on ClinicalTrials.gov

Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

July 31, 2009

Conditions
Healthy, no Evidence of Disease
Interventions
DRUG

Se-methyl-seleno-L-cysteine

Given orally

OTHER

placebo

Given orally

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

60611

Northwestern University, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00489372 - Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients | Biotech Hunter | Biotech Hunter